Results 31 to 40 of about 22,497,798 (252)

The relationship between oxidized lipoprotein(a) and carotid atherosclerosis in asymptomatic subjects: A comparison with native lipoprotein(a)

open access: yesLipids in Health and Disease, 2011
Background Oxidized lipoprotein(a) (oxLp(a)) can be a more potent marker of atherogenesis than native Lp(a), although Lp(a) is considered to be a risk factor for atherosclerotic diseases.
Taniguchi Nobuyuki   +4 more
doaj   +1 more source

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease

open access: yesOpen Heart, 2022
Objective Lipoprotein(a) (Lp(a)) is an important genetically determined risk factor for atherosclerotic vascular disease (ASCVD). With the development of Lp(a)-lowering therapies, this study sought to characterise patterns of Lp(a) levels in a global ...
Ulf Landmesser   +23 more
doaj   +1 more source

Relationship between lipoprotein(a) and colorectal cancer among inpatients: a retrospective study

open access: yesFrontiers in Oncology, 2023
The present study was to explore the association between lipoprotein(a) [Lp(a)] and colorectal cancer (CRC) among inpatients. This study included 2822 participants (393 cases vs. 2429 controls) between April 2015 and June 2022. Logistic regression models,
Huijie Wang   +7 more
doaj   +1 more source

Association between serum lipoprotein(a) and mildly reduced eGFR: a cross-sectional study

open access: yesBMC Nephrology, 2023
Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease (CVD) and aortic stenosis. However, the data on the relationship between Lp(a) and mildly reduced estimated glomerular filtration rate (eGFR) has been disputed.
Hong Zhang   +8 more
doaj   +1 more source

Laboratorijsko testiranje trombofilije u djece

open access: yesLiječnički vjesnik, 2023
Pojam trombofilija obično se koristi za opisivanje nasljednih i/ili stečenih stanja povezanih s povećanom sklonošću za nastanak tromboze i klinički se odnosi na pacijente koji razvijaju spontanu vensku tromboemboliju (VTE).
Irena Drmić Hofman, Nina Kalajžić
doaj   +1 more source

Lipoproteína (a) e fatores de risco cardiovascular em crianças e adolescentes

open access: yes, 2013
Objective: To review the relationship between lipo- protein (a) (Lp(a)) and other risk factors for cardiovascular disease (CVD) in children and adolescents.
Á. C. Palmeira   +5 more
semanticscholar   +1 more source

Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol‐Lowering Therapy

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Elevated lipoprotein(a) (Lp(a)), a low‐density lipoprotein‐like particle bound to the polymorphic apolipoprotein(a) (apo(a)), may be causal for cardiovascular disease. However, the metabolism of Lp(a) in humans is poorly understood.
Dick C. Chan   +5 more
doaj   +1 more source

Trp64Arg polymorphism of the ADRB3 gene associated with maximal fat oxidation and LDL‐C levels in non‐obese adolescents

open access: yesJornal de Pediatria (Versão em Português), 2018
Objective: To analyze the association between the Trp64Arg polymorphism of the ADRB3 gene, maximal fat oxidation rates and the lipid profile levels in non-obese adolescents.
Íncare Correa de Jesus   +8 more
doaj   +2 more sources

MIKRONUTRIJENTI U PREVENCIJI KARDIOVASKULARNIH BOLESTI [PDF]

open access: yes, 2015
Značenje vitamina i drugih staničnih hranjivih tvari za metabolizam tjelesnih stanica temelj je stanične medicine. Njen utemeljitelj dr. Matthias Rath, više od trideset godina istražuje mogućnosti sprečavanja kardiovaskularnih bolesti kao najčešćih ...
Tatjana Stibilj Batinić, Vedrana Nucak
core   +2 more sources

Adherencija i propisivanje statina u primarnoj prevenciji unutar primarne zdravstvene zaštite [PDF]

open access: yes, 2021
Uz slabo dijagnosticiranu porodičnu hiperkolesterolemiju, sekundarna hiperkolesterolemija vrlo je čest i zanemaren problem u svakodnevnoj kliničkoj praksi.
Ivor Jelavić   +2 more
core   +3 more sources

Home - About - Disclaimer - Privacy